Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Correspondence: Trends in Retina Specialist Imaging Utilization From 2012 to 2016 in the United States Medicare Fee-for-Service Population.

Pontikos N, Wagner SK, Balaskas K, Faes L, Kortuem K, Fasler K, Keane PA.

Am J Ophthalmol. 2019 Nov 15. pii: S0002-9394(19)30479-9. doi: 10.1016/j.ajo.2019.09.021. [Epub ahead of print] No abstract available.

PMID:
31735254
2.

Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.

Fasler K, Fu DJ, Moraes G, Wagner S, Gokhale E, Kortuem K, Chopra R, Faes L, Preston G, Pontikos N, Patel PJ, Tufail A, Lee AY, Balaskas K, Keane PA.

Br J Ophthalmol. 2019 Oct 14. pii: bjophthalmol-2019-314446. doi: 10.1136/bjophthalmol-2019-314446. [Epub ahead of print]

PMID:
31611234
3.

Implementation of a cloud-based referral platform in ophthalmology: making telemedicine services a reality in eye care.

Kern C, Fu DJ, Kortuem K, Huemer J, Barker D, Davis A, Balaskas K, Keane PA, McKinnon T, Sim DA.

Br J Ophthalmol. 2019 Jul 18. pii: bjophthalmol-2019-314161. doi: 10.1136/bjophthalmol-2019-314161. [Epub ahead of print]

4.

Comparing diabetic retinopathy lesions in scanning laser ophthalmoscopy and colour fundus photography.

Nghiem AZ, Nderitu P, Lukic M, Khatun M, Largan R, Kortuem K, Balaskas K, Sim D.

Acta Ophthalmol. 2019 Dec;97(8):e1035-e1040. doi: 10.1111/aos.14106. Epub 2019 Jul 8.

PMID:
31286663
5.

One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.

Fasler K, Moraes G, Wagner S, Kortuem KU, Chopra R, Faes L, Preston G, Pontikos N, Fu DJ, Patel P, Tufail A, Lee AY, Balaskas K, Keane PA.

BMJ Open. 2019 Jun 21;9(6):e027441. doi: 10.1136/bmjopen-2018-027441.

6.

Clinical Outcomes of a Hospital-Based Teleophthalmology Service: What Happens to Patients in a Virtual Clinic?

Kern C, Kortuem K, Hamilton R, Fasolo S, Cai Y, Balaskas K, Keane P, Sim D.

Ophthalmol Retina. 2019 May;3(5):422-428. doi: 10.1016/j.oret.2019.01.011. Epub 2019 Jan 21.

PMID:
31044734
7.

Evaluation of a computed-tomography-based assessment scheme in treatment decision-making for isolated orbital floor fractures.

Frohwitter G, Wimmer S, Goetz C, Weitz J, Ulbig M, Kortuem KU, Dangelmaier J, Ritschl L, Doll C, Ristow O, Kesting MR, Koerdt S.

J Craniomaxillofac Surg. 2018 Sep;46(9):1550-1554. doi: 10.1016/j.jcms.2018.06.016. Epub 2018 Jul 11.

PMID:
30075904
8.

Modern Corneal Eye-Banking Using a Software-Based IT Management Solution.

Kern C, Kortuem K, Wertheimer C, Nilmayer O, Dirisamer M, Priglinger S, Mayer WJ.

J Ophthalmol. 2018 May 20;2018:2645280. doi: 10.1155/2018/2645280. eCollection 2018.

9.

Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration.

Rohm M, Tresp V, Müller M, Kern C, Manakov I, Weiss M, Sim DA, Priglinger S, Keane PA, Kortuem K.

Ophthalmology. 2018 Jul;125(7):1028-1036. doi: 10.1016/j.ophtha.2017.12.034. Epub 2018 Feb 14.

PMID:
29454659
10.

Implementation of medical retina virtual clinics in a tertiary eye care referral centre.

Kortuem K, Fasler K, Charnley A, Khambati H, Fasolo S, Katz M, Balaskas K, Rajendram R, Hamilton R, Keane PA, Sim DA.

Br J Ophthalmol. 2018 Oct;102(10):1391-1395. doi: 10.1136/bjophthalmol-2017-311494. Epub 2018 Jan 6.

PMID:
29306863
11.

Differences in corneal clinical findings after standard and accelerated cross-linking in patients with progressive keratoconus.

Kortuem KU, Vounotrypidis E, Athanasiou A, Müller M, Babenko A, Kern C, Priglinger S, Mayer WJ.

BMC Ophthalmol. 2017 Nov 28;17(1):222. doi: 10.1186/s12886-017-0610-4.

12.

COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.

Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, Kreutzer T, Schiefelbein J, Rottmann M, Priglinger S, KortUEm KU.

Retina. 2018 Dec;38(12):2293-2300. doi: 10.1097/IAE.0000000000001892.

PMID:
29068914
13.

Comparison of visual outcomes, alignment accuracy, and surgical time between 2 methods of corneal marking for toric intraocular lens implantation.

Mayer WJ, Kreutzer T, Dirisamer M, Kern C, Kortuem K, Vounotrypidis E, Priglinger S, Kook D.

J Cataract Refract Surg. 2017 Oct;43(10):1281-1286. doi: 10.1016/j.jcrs.2017.07.030. Epub 2017 Oct 19.

PMID:
29056301
14.

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK.

Blood Cancer J. 2016 Feb 26;6:e397. doi: 10.1038/bcj.2016.1.

15.

RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.

Zhu YX, Yin H, Bruins LA, Shi CX, Jedlowski P, Aziz M, Sereduk C, Kortuem KM, Schmidt JE, Champion M, Braggio E, Keith Stewart A.

Blood. 2015 Jan 15;125(3):483-91. doi: 10.1182/blood-2014-05-577130. Epub 2014 Nov 13.

16.

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK.

Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.

17.

Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.

Kortuem KM, Zidich K, Schuster SR, Khan ML, Jimenez-Zepeda VH, Mikhael JR, Fonseca R, Stewart AK.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):284-290.e5. doi: 10.1016/j.clml.2013.12.015. Epub 2013 Dec 28.

18.

Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.

Egan JB, Barrett MT, Champion MD, Middha S, Lenkiewicz E, Evers L, Francis P, Schmidt J, Shi CX, Van Wier S, Badar S, Ahmann G, Kortuem KM, Boczek NJ, Fonseca R, Craig DW, Carpten JD, Borad MJ, Stewart AK.

PLoS One. 2014 Feb 5;9(2):e87113. doi: 10.1371/journal.pone.0087113. eCollection 2014.

19.

The clinical significance of cereblon expression in multiple myeloma.

Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK.

Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.

20.

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK.

Leukemia. 2013 Dec;27(12):2357-65. doi: 10.1038/leu.2013.172. Epub 2013 Jun 11.

21.

Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.

Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, Liang WS, Craig DW, Carpten JD, Stewart AK.

Br J Haematol. 2013 Jun;161(5):748-51. doi: 10.1111/bjh.12291. Epub 2013 Mar 11. No abstract available.

22.

Carfilzomib.

Kortuem KM, Stewart AK.

Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883. Review.

PMID:
23393020
23.

Evaluation of a vision-related utility instrument: the German vision and quality of life index.

Finger RP, Kortuem K, Fenwick E, von Livonius B, Keeffe JE, Hirneiss CW.

Invest Ophthalmol Vis Sci. 2013 Feb 1;54(2):1289-94. doi: 10.1167/iovs.12-10828.

PMID:
23341011
24.

Optimizing visualization in enhanced depth imaging OCT in healthy subjects and patients with retinal pigment epithelial detachment.

Reznicek L, Vounotrypidis E, Seidensticker F, Kortuem K, Kampik A, Neubauer AS, Wolf A.

Clin Ophthalmol. 2012;6:1915-20. doi: 10.2147/OPTH.S35596. Epub 2012 Nov 21.

25.

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.

Zhu YX, Kortuem KM, Stewart AK.

Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. Review.

26.

Melanocytes in nonlesional sun-exposed skin: a multicenter comparative study.

Hendi A, Wada DA, Jacobs MA, Crook JE, Kortuem KR, Weed BR, Otley CC, Gibson LE.

J Am Acad Dermatol. 2011 Dec;65(6):1186-93. doi: 10.1016/j.jaad.2010.10.039. Epub 2011 Jun 17.

PMID:
21684036
27.

Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review.

Kortuem KR, Davis MD, Witman PM, McEvoy MT, Farmer SA.

Pediatr Dermatol. 2010 Sep-Oct;27(5):518-24. doi: 10.1111/j.1525-1470.2010.01124.x.

PMID:
21182642
28.

A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis.

Billet SE, Kortuem KR, Gibson LE, El-Azhary R.

Arch Dermatol. 2008 Jun;144(6):774-8. doi: 10.1001/archderm.144.6.774.

PMID:
18559768
29.

Index of suspicion.

Absi MA, Kin LL, Hanna A, Matthews G, Brands CK, Kortuem K, Davis M, Pane LA.

Pediatr Rev. 2008 Feb;29(2):61-6. doi: 10.1542/pir.29-2-61. No abstract available.

PMID:
18245302
30.

Reduced redox state allows prolonged survival of axotomized neonatal retinal ganglion cells.

Geiger LK, Kortuem KR, Alexejun C, Levin LA.

Neuroscience. 2002;109(3):635-42.

PMID:
11823072
31.

Differential susceptibility of retinal ganglion cells to reactive oxygen species.

Kortuem K, Geiger LK, Levin LA.

Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3176-82.

PMID:
10967081

Supplemental Content

Loading ...
Support Center